GlassScriptPhysician profile
John C Mavropoulos
NPI 1063737682
$3,029.69
in general payments reported to CMS, 2019-2025
27 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.44 · 2021: $224 · 2022: $1,183 · 2023: $702 · 2024: $609 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686.89 | 2021-2025 | |
| Organogenesis INC. | $420.78 | 2021-2025 | Puraply, Cygnus Dual |
| Kerecis Limited | $317.45 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Leo Pharma INC. | $314.96 | 2022-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $227.73 | 2022-2025 | Dupixent |
| Eli Lilly and Company | $175.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $146.14 | 2019-2023 | Ilumya, Blu-U |
| Lilly USA, LLC | $99.31 | 2022-2025 | Ebglyss, Taltz |
| Incyte Corporation | $76.59 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $75.51 | 2022-2023 | Sotyktu |
| Smith+Nephew, INC. | $66.60 | 2023-2025 | Grafix Pl, Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.42 | 2022-2023 | Spevigo |
| Janssen Biotech, INC. | $52.20 | 2022-2023 | Tremfya |
| Galderma Laboratories, L.P. | $50.19 | 2021-2023 | |
| Misonix INC | $46.32 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $40.00 | 2022 | |
| Epi Health, LLC | $38.88 | 2022 | |
| Organon LLC | $29.01 | 2025 | |
| Biofrontera INC. | $20.60 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Pfizer INC. | $18.21 | 2023 | |
| Dusa Pharmaceuticals, INC. | $15.74 | 2019 | |
| Ucb, INC. | $15.36 | 2023 | Cimzia |
| Sebela Pharmaceuticals INC. | $14.59 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.33 | 2024 | Jublia, Cabtreo, Arazlo |
| Mimedx Group, INC. | $13.88 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mavropoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.